summit
therapeutics
announces
court
approval
scheme
summit
therapeutics
plc
summit
company
summit
therapeutics
announces
court
approval
scheme
expects
complete
redomiciliation
delaware
usa
september
oxford
uk
cambridge
us
september
summit
therapeutics
plc
nasdaq
smmt
led
billionaire
investor
robert
duggan
executive
chairman
chief
executive
officer
majority
shareholder
pleased
announce
september
expects
complete
redomiciliation
delaware
usa
mr
duggan
summit
board
directors
extend
appreciation
high
court
justice
england
wales
sanctioned
september
scheme
arrangements
part
companies
act
scheme
pursuant
summit
therapeutics
become
new
delaware
usa
incorporated
holding
company
summit
therapeutics
plc
subsidiaries
scheme
expected
become
effective
therefore
complete
september
subject
effectiveness
scheme
expected
last
day
trading
summit
therapeutics
plc
american
depositary
shares
nasdaq
global
market
september
common
stock
summit
therapeutics
expected
begin
trading
nasdaq
global
market
ticker
symbol
smmt
september
since
ratio
ordinary
shares
summit
therapeutics
plc
exchanged
shares
common
stock
summit
therapeutics
equal
ratio
ordinary
shares
american
depositary
shares
adjustment
nasdaq
trading
price
made
connection
listing
common
stock
summit
therapeutics
summit
therapeutics
summit
therapeutics
empowered
discuva
platform
company
innovative
antibiotic
discovery
engine
led
ventzislav
stefanov
supported
barda
funding
intends
leader
patient
physician
friendly
paradigm
shifting
antibiotic
innovation
new
mechanism
antibiotics
designed
become
new
era
working
harmony
human
microbiome
treat
prospective
patients
suffering
infectious
disease
initially
focussing
clostridioides
difficile
infections
cdi
estimated
impact
million
patients
worldwide
annually
commercialization
ridinilazole
treatment
cdi
subject
regulatory
approvals
overriding
objective
summit
therapeutics
create
value
patients
hospital
infectious
disease
care
givers
community
based
infectious
disease
healthcare
providers
well
healthcare
payors
around
world
currently
summit
lead
product
ridinilazole
engaged
two
global
phase
iii
trials
enrolling
patient
vs
standard
care
vancomycin
treatment
difficile
infections
summit
vision
mission
extend
pipeline
development
new
mechanism
narrow
spectrum
microbiome
sparing
antibiotics
targeting
difficile
enterobacteriaceae
escherichia
coli
klebsiella
pneumoniae
bacterial
infections
high
unmet
medical
need
information
visit
follow
us
twitter
summitplc
information
company
discuva
platform
visit
https
contacts
summit
press
office
investors
summit
statements
statements
press
release
company
future
expectations
plans
prospects
including
limited
statements
proposed
redomiciliation
clinical
preclinical
development
company
product
candidates
therapeutic
potential
company
product
candidates
potential
commercialization
company
product
candidates
timing
initiation
completion
availability
data
clinical
trials
potential
submission
applications
marketing
approvals
statements
containing
words
anticipate
believe
continue
could
estimate
expect
intend
may
plan
potential
predict
project
target
would
similar
expressions
constitute
statements
within
meaning
private
securities
litigation
reform
act
actual
results
may
differ
materially
indicated
statements
result
various
important
factors
including
uncertainties
inherent
initiation
future
clinical
trials
availability
timing
data
ongoing
future
clinical
trials
results
trials
whether
preliminary
results
clinical
trial
predictive
final
results
trial
whether
results
early
clinical
trials
preclinical
studies
indicative
results
later
clinical
trials
expectations
regulatory
approvals
laws
regulations
affecting
government
contracts
funding
awards
availability
funding
sufficient
company
foreseeable
unforeseeable
operating
expenses
capital
expenditure
requirements
factors
discussed
risk
factors
section
filings
company
makes
securities
exchange
commission
including
company
transition
report
form
eleven
months
ended
december
accordingly
readers
place
undue
reliance
statements
information
addition
statements
included
press
release
represent
company
views
date
release
relied
upon
representing
company
views
subsequent
date
company
specifically
disclaims
obligation
update
statements
included
press
release
